Kaken Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
Kaken Pharmaceutical has a total shareholder equity of ¥140.1B and total debt of ¥3.9B, which brings its debt-to-equity ratio to 2.7%. Its total assets and total liabilities are ¥168.3B and ¥28.2B respectively. Kaken Pharmaceutical's EBIT is ¥4.5B making its interest coverage ratio -9.8. It has cash and short-term investments of ¥66.2B.
Key information
2.7%
Debt to equity ratio
JP¥3.85b
Debt
Interest coverage ratio | -9.8x |
Cash | JP¥66.15b |
Equity | JP¥140.14b |
Total liabilities | JP¥28.20b |
Total assets | JP¥168.34b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: 4521's short term assets (¥110.3B) exceed its short term liabilities (¥19.6B).
Long Term Liabilities: 4521's short term assets (¥110.3B) exceed its long term liabilities (¥8.7B).
Debt to Equity History and Analysis
Debt Level: 4521 has more cash than its total debt.
Reducing Debt: 4521's debt to equity ratio has reduced from 3.3% to 2.7% over the past 5 years.
Debt Coverage: 4521's debt is well covered by operating cash flow (67%).
Interest Coverage: 4521 earns more interest than it pays, so coverage of interest payments is not a concern.